BioCorteX valuation, funding and investors
BioCorteX works in biotechnology research and development, based in London, United Kingdom. Founded in 2021, it has about 13 employees.
- Last round
- Seed · $5.00M · Mar 2023
- Valuation at last round
- $30.6M · implied
- Headcount
- 13 · down
- Grade
- D
- Founded
- 2021
BioCorteX valuation today
VCMC values BioCorteX at $9.34M today, with a range of $3.85M to $47.4M and a grade of D. The valuation starts from its last funding round, a seed round in Mar 2023.
Valuation by date (71 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2021 | $10.7M | $3.89M – $29.3M | $11.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $10.8M | $3.93M – $29.6M | $12.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $10.9M | $3.96M – $29.9M | $12.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $11.0M | $3.99M – $30.1M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $11.1M | $4.03M – $30.4M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $11.2M | $4.07M – $30.7M | $12.3M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $11.3M | $4.10M – $31.0M | $12.4M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $11.4M | $4.14M – $31.2M | $12.5M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $11.5M | $4.18M – $31.5M | $12.6M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $11.6M | $4.22M – $31.8M | $12.7M (+10%) | before first round | – | unknown | D | 0% |
| 1 Nov 2021 | $11.7M | $4.25M – $32.1M | $12.8M (+10%) | before first round | – | unknown | D | 0% |
| 1 Dec 2021 | $11.8M | $4.29M – $32.4M | $12.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2022 | $11.9M | $4.33M – $32.7M | $13.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $12.0M | $4.36M – $32.9M | $13.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2022 | $12.1M | $4.39M – $33.2M | $13.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2022 | $12.2M | $4.43M – $33.4M | $13.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2022 | $12.2M | $4.46M – $33.6M | $13.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2022 | $12.3M | $4.49M – $33.9M | $13.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2022 | $12.4M | $4.53M – $34.1M | $13.6M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2022 | $12.5M | $4.56M – $34.4M | $13.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Sep 2022 | $12.6M | $4.59M – $34.7M | $13.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Oct 2022 | $12.7M | $4.63M – $34.9M | $13.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Nov 2022 | $12.8M | $4.66M – $35.2M | $14.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Dec 2022 | $12.9M | $4.70M – $35.4M | $14.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2023 | $13.0M | $4.73M – $35.7M | $14.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2023 | $13.1M | $4.77M – $36.0M | $14.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2023 | $13.2M | $4.80M – $36.2M | $14.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2023 | $30.6M | $20.1M – $93.1M | $61.2M (+100%) | after a round | – | unknown | C | 0% |
| 1 May 2023 | $32.4M | $20.1M – $93.1M | $61.2M (+89%) | after a round | – | unknown | C | 0% |
| 1 Jun 2023 | $34.4M | $20.1M – $93.1M | $61.2M (+78%) | after a round | – | unknown | C | 0% |
| 1 Jul 2023 | $36.4M | $20.1M – $93.1M | $61.2M (+68%) | after a round | – | unknown | C | 0% |
| 1 Aug 2023 | $38.6M | $20.1M – $93.1M | $61.2M (+58%) | after a round | – | unknown | C | 0% |
| 1 Sep 2023 | $41.0M | $20.1M – $93.1M | $61.2M (+49%) | after a round | – | unknown | C | 0% |
| 1 Oct 2023 | $43.4M | $20.1M – $93.1M | $61.2M (+41%) | after a round | – | unknown | C | 0% |
| 1 Nov 2023 | $46.0M | $20.1M – $93.1M | $61.2M (+33%) | after a round | 13 | unknown | C | 0% |
| 1 Dec 2023 | $48.7M | $20.1M – $93.1M | $61.2M (+26%) | after a round | 13 | unknown | C | 0% |
| 1 Jan 2024 | $51.6M | $20.1M – $93.1M | $61.2M (+18%) | after a round | 13 | unknown | C | 0% |
| 1 Feb 2024 | $54.8M | $20.1M – $93.1M | $61.2M (+12%) | after a round | 13 | unknown | C | 0% |
| 1 Mar 2024 | $44.8M | $20.1M – $70.5M | $41.1M (-8%) | after a round | 12 | flat | C | 40% |
| 1 Apr 2024 | $47.4M | $20.0M – $72.2M | $40.5M (-14%) | after a round | 13 | flat | C | 37% |
| 1 May 2024 | $47.9M | $19.1M – $74.3M | $41.4M (-14%) | after a round | 13 | flat | C | 34% |
| 1 Jun 2024 | $48.4M | $18.1M – $76.3M | $42.2M (-13%) | after a round | 13 | flat | C | 31% |
| 1 Jul 2024 | $49.0M | $17.3M – $78.1M | $43.1M (-12%) | after a round | 13 | flat | C | 29% |
| 1 Aug 2024 | $49.5M | $16.4M – $79.8M | $43.9M (-11%) | after a round | 13 | flat | C | 26% |
| 1 Sep 2024 | $50.0M | $16.9M – $81.3M | $44.7M (-11%) | after a round | 15 | up | C | 24% |
| 1 Oct 2024 | $50.5M | $16.3M – $82.6M | $45.5M (-10%) | after a round | 15 | up | C | 22% |
| 1 Nov 2024 | $51.0M | $15.8M – $83.9M | $46.2M (-9%) | after a round | 15 | up | C | 21% |
| 1 Dec 2024 | $51.5M | $15.3M – $85.0M | $46.9M (-9%) | after a round | 15 | up | C | 19% |
| 1 Jan 2025 | $51.9M | $14.9M – $86.0M | $47.7M (-8%) | after a round | 15 | up | C | 17% |
| 1 Feb 2025 | $52.4M | $14.4M – $87.0M | $48.3M (-8%) | after a round | 15 | up | C | 16% |
| 1 Mar 2025 | $52.8M | $14.0M – $87.7M | $49.0M (-7%) | after a round | 15 | up | C | 15% |
| 1 Apr 2025 | $52.6M | $11.8M – $85.4M | $49.6M (-6%) | after a round | 15 | up | C | 14% |
| 1 May 2025 | $53.0M | $11.3M – $86.1M | $50.1M (-5%) | after a round | 15 | up | D | 12% |
| 1 Jun 2025 | $53.4M | $10.8M – $86.7M | $50.6M (-5%) | after a round | 15 | up | D | 11% |
| 1 Jul 2025 | $53.8M | $10.4M – $87.2M | $51.0M (-5%) | after a round | 15 | up | D | 11% |
| 1 Aug 2025 | $54.1M | $9.92M – $87.7M | $51.6M (-5%) | after a round | 16 | up | D | 10% |
| 1 Sep 2025 | $54.5M | $9.49M – $88.2M | $51.5M (-5%) | after a round | 16 | up | D | 9% |
| 1 Oct 2025 | $54.8M | $8.14M – $88.6M | $51.0M (-7%) | after a round | 16 | flat | D | 8% |
| 1 Nov 2025 | $55.2M | $7.74M – $89.0M | $51.1M (-7%) | after a round | 16 | flat | D | 8% |
| 1 Dec 2025 | $55.5M | $7.37M – $89.3M | $51.3M (-8%) | after a round | 16 | flat | D | 7% |
| 1 Jan 2026 | $55.8M | $7.00M – $89.6M | $51.4M (-8%) | after a round | 16 | flat | D | 6% |
| 1 Feb 2026 | $56.1M | $6.65M – $89.9M | $51.4M (-8%) | after a round | 16 | flat | D | 6% |
| 1 Mar 2026 | $56.4M | $6.36M – $90.2M | $51.4M (-9%) | after a round | 16 | flat | D | 5% |
| 1 Apr 2026 | $58.7M | $6.04M – $91.6M | $54.0M (-8%) | after a round | 16 | flat | D | 3% |
| 1 May 2026 | $58.5M | $5.75M – $91.1M | $53.8M (-8%) | after a round | 16 | flat | D | 2% |
| 1 Jun 2026 | $12.6M | $5.46M – $51.0M | $8.85M (-30%) | after a round | 13 | down | D | 97% |
| 1 Jul 2026 | $12.4M | $5.20M – $50.5M | $8.70M (-30%) | after a round | 14 | down | D | 96% |
| 1 Aug 2026 | $11.9M | $4.94M – $49.8M | $8.38M (-29%) | after a round | 14 | down | D | 96% |
| 1 Sep 2026 | $11.8M | $4.70M – $49.6M | $8.38M (-29%) | after a round | 14 | down | D | 94% |
| 1 Oct 2026 | $10.8M | $4.47M – $47.9M | $7.62M (-29%) | after a round | 13 | down | D | 97% |
| 24 Oct 2026 | $9.34M | $3.85M – $47.4M | $6.84M (-27%) | after a round | 13 | down | D | 97% |
Key facts about BioCorteX
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- about 13 -19% in a year
- Total raised
- $5.0M
- Funding rounds
- 1
- Last round
- Seed Mar 2023
BioCorteX funding history
BioCorteX has 1 funding round on record, from Mar 2023 to Mar 2023, $5.0M in total. None disclosed a valuation.
Seed 31 Mar 2023
Led by Sofinnova Partners, Hoxton Ventures.
Sources: finsmes.com, cambridgebiocapital.substack.com, cambridgebiocapital.com
$5.0M
BioCorteX investors
2 investors have backed BioCorteX; Hoxton Ventures and Sofinnova Partners led at least one round.
What BioCorteX does
BioCorteX works in biotechnology, with 8 recorded offerings and customers in biotechnology, pharmaceuticals and healthcare.
BioCorteX Ltd is a British biotechnology company engaged in drug discovery and development, with a focus on the microbiome. The company operates as a research and experimental development entity, utilizing proprietary platforms to simulate interactions between bacteria, the human immune system, diseases, and pharmaceutical interventions. BioCorteX also develops a comprehensive knowledge graph of microbiome samples and provides insights to support drug development processes. The company collaborates with partners in precision oncology and cloud-based drug development.
Description from Veridion's company data.
Products and services
- Biotechnology Research and Development
- Drug Discovery and Development Services
- Microbiome Data Integration and Analysis
- Foundational Emulator Simulation Services
- Microbiome-Drug Interaction Research
- Precision Oncology Solutions Development
- Pharmaceutical Accessibility Solutions
- Global Pharmaceutical Partnership Development
Markets
- Biotechnology
- Pharmaceuticals
- Healthcare
Technology
- Foundational Emulator for Microbiome Simulation
- Comprehensive Microbiome Knowledge Graph
Business model
- Business-to-Business
- Enterprise
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about BioCorteX
What is BioCorteX worth?
Valuation $9.34M (range $3.85M to $47.4M), as of 24 Oct 2026.
Has BioCorteX raised money?
BioCorteX has 1 funding round on record, from Mar 2023 to Mar 2023, $5.0M in total. None disclosed a valuation.
Who has invested in BioCorteX?
Hoxton Ventures and Sofinnova Partners. Lead investors include Hoxton Ventures and Sofinnova Partners.
How many people work at BioCorteX?
About 13, down 19% over the last year. Headcount rose from 13 in Oct 2023 to 16 in Jul 2025, then fell to 13 in Sep 2026.
What does BioCorteX do?
BioCorteX works in biotechnology, with 8 recorded offerings and customers in biotechnology, pharmaceuticals and healthcare. Its main offerings are biotechnology research and development, drug discovery and development services and microbiome data integration and analysis.
When was BioCorteX founded, and where is it based?
BioCorteX was founded in 2021 and is based in London, United Kingdom. It has about 13 employees, down 19% over the last year.